TY  - JOUR 
AU  - Romero Pérez, Inés
AU  - Díaz Rodríguez, María Elena
AU  - Sánchez Díaz, Laura
AU  - Montero González, Juan Carlos
AU  - Pandiella Alonso, Atanasio
PY  - 2024
SN  - 2157-9024
UR  - http://hdl.handle.net/10366/171499
AB  - [EN]Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. However, despite its clinical benefit, resistance to the drug may arise. Here we have created cellular models of neratinib resistance to...
LA  - eng
PB  - Springer Nature
KW  - Breast cancer
KW  - Drug resistance
KW  - HER2
KW  - Neratinib
KW  - Drug Resistance
TI  - Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
DO  - 10.1038/s41389-024-00531-4
T2  - Oncogenesis
VL  - 13
ER  -